Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px
Document › Details

Sablebio Ltd. (Sable Bio). (2/6/24). "Press Release: Sable Bio Raises £1.5m Pre-seed Round to Transform Drug Discovery Safety Assessments". London.

Organisations Organisation Sablebio Ltd. (Sable Bio)
  Organisation 2 Episode1 Ventures LLP
Products Product AI-based drug discovery software
  Product 2 venture capital
Index term Index term Sablebio–SEVERAL: investment, 202402 pre-seed financing round £1.5m led by Episode 1 Ventures
Persons Person Almond-Thynne, Joshua (Sablebio 202308– Director + Co-Founder before BenevolentAI)
  Person 2 Jayakumar, Siddhant M. (Finster AI 202402 CEO + Founder before Google DeepMind)
     


> Established by a team of AI-driven drug discovery experts formerly at BenevolentAI, Sable aims to provide scientists with richer specialist data, initially concentrating on toxicology.

> Sable offers an AI-enhanced platform that seamlessly integrates multimodal data to produce actionable insights.The London-based company raised an oversubscribed £1.5 million pre-seed funding round, led by Episode 1 Ventures with participation from Seedcamp.

> The funding will enable the refinement and enhancement of their core technological infrastructure, providing a solid and expansive foundation for their data capabilities.

London, FEBRUARY 06, 2024

Sable Bio, an innovative B2B software startup changing how biotech and pharma companies evaluate drug target safety for effective decision-making, today announced the successful closure of an oversubscribed £1.5 million pre-seed funding round, Episode 1 Ventures supported by Seedcamp, and ex-Deepmind, now Finster AI CEO Siddhant Jayakumar.

Sable facilitates broad access to specialist biomedical data, empowering scientists across different fields to make well-informed decisions about the safety of specific drug targets.

With unforeseen toxicity as a major driver of failure in drug discovery campaigns, Sable's approach offers substantial cost and time savings in drug development, delivering safer drugs to patients in need more rapidly.

Founded in 2023 and headquartered in London, Sable helps scientists identify and mitigate potential safety risks for drugs in development or about to enter the clinic, using a suite of state of the art techniques.

The company is currently seeking to establish partnerships with biotech, pharma, and healthtech companies, as well as academic collaborations.

The funding will enable building out a stellar team of scientists and engineers, enabling the refinement and enhancement of their core technological infrastructure, providing a solid and expansive foundation for their data capabilities.


Josh Almond-Thynne – Co-founder:
“Taking drugs to market from discovery to development and beyond takes far too long and toxicity is a major factor adding delays or causing such processes to fail entirely. Sable is perfectly positioned to solve this problem by providing access to the right data at the right time to those who need it, leveraging LLMs to surface data that would have previously been impossible to cover fully. Alex and Josh as co-founders have the ideal blend of scientific excellence, specific domain experience and entrepreneurially drive to be building Sable and we're delighted to have the opportunity to partner with them.”


[ Adam Shuaib ] Adam @ Episode 1:
“Taking drugs to market from discovery to development and beyond takes far too long and toxicity is a major factor adding delays or causing such processes to fail entirely. Sable is perfectly positioned to solve this problem by providing access to the right data at the right time to those who need it, leveraging LLMs to surface data that would have previously been impossible to cover fully. Alex and Josh as co-founders have the ideal blend of scientific excellence, specific domain experience and entrepreneurially drive to be building Sable and we're delighted to have the opportunity to partner with them.”


[ Tom Wilson ] Tom @ Seedcamp:
“Taking drugs to market from discovery to development and beyond takes far too long and toxicity is a major factor adding delays or causing such processes to fail entirely. Sable is perfectly positioned to solve this problem by providing access to the right data at the right time to those who need it, leveraging LLMs to surface data that would have previously been impossible to cover fully. Alex and Josh as co-founders have the ideal blend of scientific excellence, specific domain experience and entrepreneurially drive to be building Sable and we're delighted to have the opportunity to partner with them.”


About Sable Bio

Sable Bio is developing a unique AI-enhanced platform designed to offer pharmaceutical companies predictive safety insights, mitigating the risk of clinical trial failures. Their innovative approach involves extracting proprietary signals from structured and unstructured data sources, leveraging large language models, causal inference techniques, and extensive domain knowledge.


About Episode 1

Episode 1 is a leading early-stage fund investing £500k – £2m in seed and pre-seed B2B software companies across the UK. We are a team of founders, technologists and operators who have been backing and building businesses for 20+ yrs


About Seedcamp

Seedcamp is Europe's seed fund, identifying and investing from Angel rounds to Seed in world-class founders attacking large, global markets and solving real problems using technology. The Seedcamp Nation includes over 490 startups building breakout businesses that change the way people live, interact and buy, and includes publicly listed UiPath, Wise, and unicorns Revolut, Synthesia, Sorare, Pleo, wefox, and Grover, along with fast-growing businesses such as Peppy, Sylvera, Appwrite, Ramp and Buynomics. Seedcamp fast-tracks a founder's vision and creates value through immediate access to smart capital, a lifelong community of support, and a global network built upon more than 15 years’ experience backing exceptional talent.

   
Record changed: 2024-03-14

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x300px




» top